drugset / Trial / NCT05560516

Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

NCT05560516

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine 60 mg daily.

Timeline

Start
2022-12-01
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 8 % Topical
Subject Capsaicin Small molecule 179 mg Topical
Comparator Duloxetine Small molecule 60 mg